BioCentury
ARTICLE | Clinical News

Forxiga dapagliflozin regulatory update

November 19, 2012 8:00 AM UTC

Bristol-Myers and partner AstraZeneca said the European Commission approved Forxiga dapagliflozin to treat Type II diabetes. The partners said the approval is the first for a sodium-glucose cotransporter 2 (SGLT2) inhibitor for diabetes. Bristol-Myers said the timing of the drug's launch will depend on pricing negotiations in each country, adding that it is "too early to discuss specific details around pricing." ...